HOWL

0.94004.64%
MC

Meeta Chatterjee

Independent Director

Dr. Meeta Chatterjee, Ph. D., has been an Independent Director of Werewolf Therapeutics, Inc. since October 2021. She served as Senior Vice President of Global Business Development at Legend Biotech Corporation since March 2019 until November 2022. Dr. Chatterjee was Chief Strategy Officer of Sun Pharmaceutical Industries Ltd. She was previously Head of Strategy, Transactions and Operations within the Business Development and Licensing (BD&L) group at Merck Research Labs. From November 2007 to May 2018, she served in roles of increasing seniority and responsibility at Merck Research Laboratories, a division of Merck & Co., Inc. Dr. Chatterjee oversaw discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies. She was responsible for Merck’s BD&L governance, oversight and control as well as out-licensing efforts. She had been a Director of Editas Medicine, Inc. since December 17, 2020 until December 31, 2024. Dr. Chatterjee has broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing and externalization activities. She also leads Alliance Management activities at Legend. She has led research efforts in the areas of hypertension, atherosclerosis and obesity and was an integral contributor to the discovery of ZETIA and ZONTIVITY. Dr. Chatterjee received her undergraduate education at St. Xavier’s University in Ahmedabad, India and Rutgers University (B. A., Hons Physics), New Jersey, USA. She received her Doctor of Philosophy in Physiology from Rutgers University and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia, School of Medicine, Virginia, USA. Dr Chatterjee is also active in industry and licensing focused organizations.

公司職務